Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Arcellx, Inc. (ACLX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
19.97-0.19 (-0.94%)
At close: 04:00PM EST
19.97 0.00 (0.00%)
After hours: 04:01PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Williams %R

Williams %R

Previous Close20.16
Open20.04
Bid15.00 x 1100
Ask22.16 x 1300
Day's Range19.68 - 20.32
52 Week Range6.03 - 26.91
Volume364,055
Avg. Volume517,726
Market Cap875.762M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-15.50
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est31.33
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for ACLX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Arcellx, Inc.
    Daily – Vickers Top Buyers & Sellers for 06/24/2022The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Rating
    Fair Value
    Economic Moat
    5 months agoArgus Research
View more
  • PR Newswire

    Arcellx Reports Third Quarter 2022 Financial Results and Business Progress

    Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today reported business highlights and financial results for the third quarter ended September 30, 2022.

  • TipRanks

    ‘The bear market rally has more room to run,’ Guggenheim says. Here are 2 stocks to bet on

    The October inflation numbers came out last week, and sparked solid gains in the markets. Investors were buoyed by better-than-expected price data when the Bureau of Labor Statistics’ Consumer Price Index came in at 7.7% annualized. This was below the 7.9% forecast, and a half-point lower than the September number – and it was widely taken as evidence that stubbornly high inflation of the last year or more may be starting to ease. Scott Minerd, chief investment officer from Guggenheim, doesn't b

  • Benzinga

    Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock

    Needham initiated coverage on Arcellx Inc (NASDAQ: ACLX) with a Buy rating and a price target of $31. Arcellx's lead program and main value driver is CART-ddBCMA, an autologous CAR-T therapy for relapsed or refractory (r/r) multiple myeloma (MM). With two CAR-Ts already on the market - Bristol Myers Squibb Co's (NYSE: BMY) Abecma and Johnson & Johnson's (NYSE: JNJ) Carvykti, Arcellx is a fast follower. The analyst says that early data for CART-ddBCMA supports an efficacy profile in line with the

Advertisement
Advertisement